TRAVERE THERAPEUTICS, INC. Current Liabilities
TRAVERE THERAPEUTICS, INC. (TVTX) had Current Liabilities of $152.03 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-04
- 2026-06-30: Liabilities, Current $152.03M.
- 2026-03-31: Liabilities, Current $125.44M.
- 2025-12-31: Liabilities, Current $159.90M.
- 2025-09-30: Liabilities, Current $135.07M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $152.03M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $125.44M 10-Q · filed 2026-05-04 | |
| 2025-12-31 | $159.90M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $135.07M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $189.54M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $182.46M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $200.75M 10-K · filed 2026-02-19 | |
| 2024-09-30 | $190.04M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $121.27M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $173.23M 10-Q · filed 2024-05-06 | |
| 2023-12-31 | $177.91M 10-K · filed 2025-02-21 | |
| 2023-09-30 | $139.43M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $135.71M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $130.65M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $142.16M 10-K · filed 2024-02-20 | |
| 2022-09-30 | $131.03M 10-Q · filed 2022-10-27 | |
| 2022-06-30 | $124.49M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $119.47M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $124.09M 10-K · filed 2023-02-23 | |
| 2021-09-30 | $113.16M 10-Q · filed 2021-10-29 | |
| 2021-06-30 | $96.98M 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $85.01M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $92.66M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $75.43M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $69.93M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $68.09M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $95.45M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $88.02M 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $90.59M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $104.08M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $104.62M 10-K · filed 2020-02-24 | |
| 2018-09-30 | $99.87M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $103.50M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $56.52M 10-Q · filed 2018-07-06 | |
| 2017-12-31 | $85.67M 10-K · filed 2019-02-26 | |
| 2017-09-30 | $83.90M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $79.63M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $76.56M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $83.26M 10-K · filed 2018-07-06 | |
| 2016-09-30 | $85.99M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $80.07M 10-Q · filed 2016-08-05 | |
| 2016-03-31 | $66.62M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $86.98M 10-K · filed 2017-03-01 | $85.80M 10-K · filed 2016-02-26 |
| 2015-09-30 | $101.95M 10-Q · filed 2015-11-06 | |
| 2015-06-30 | $172.38M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $102.17M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $107.54M 10-K · filed 2016-02-26 | $107.54M 10-K · filed 2015-03-11 |
| 2014-09-30 | $49.13M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $47.98M 10-Q · filed 2014-08-14 | |
| 2014-03-31 | $113.45M 10-Q · filed 2014-05-15 | |
| 2013-12-31 | $36.56M 10-K/A · filed 2015-07-09 | $35.21M 10-K · filed 2014-03-28 |
| 2013-09-30 | $30.94M 10-Q/A · filed 2015-07-09 | $27.17M 10-Q · filed 2013-11-13 |
| 2013-06-30 | $11.13M 10-Q · filed 2013-09-16 | |
| 2013-03-31 | $1.58M 10-Q/A · filed 2013-09-16 | $1.22M 10-Q · filed 2013-07-24 |
| 2012-12-31 | $5.80M 10-Q/A · filed 2015-07-09 | |
| 2012-11-30 | $68.65K 10-Q · filed 2013-03-06 | |
| 2012-08-31 | $67.99K 10-Q · filed 2012-10-10 | |
| 2012-05-31 | $67.49K 10-Q · filed 2012-08-08 | |
| 2012-02-29 | $66.99K 10-Q · filed 2013-03-06 | |
| 2011-12-31 | $555.86K 10-K/A · filed 2013-09-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |